Overview

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

Status:
Terminated

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether low dose Asacol® (27 mg/kg - 71 mg/kg) and high dose Asacol® (53 mg/kg - 118 mg/kg) are safe and effective when dosed as 400 mg delayed-release tablets given twice daily for 26 weeks to children and adolescents for the maintenance of remission of ulcerative colitis.

Phase:

Phase 3

Details

Lead Sponsor:

Warner Chilcott

Treatments:

Aminosalicylic Acid
Mesalamine